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Introduction: Lineage tracing using inducible genetic labeling has emerged to be a powerful method for
interrogating the developmental fate of cells in intact tissues. A common induction mechanism is the use of
tamoxifen-dependent Cre recombinase (CreER and CreERT2), but the effects of tamoxifen at doses normally used in
lineage-tracing studies on normal adult mammary gland homeostasis are not known.
Methods: We used flow cytometry and immunostaining of intact glands to determine whether varying doses of
tamoxifen skew the distribution and the apoptosis and proliferation status of different types of mammary epithelial
cells in vivo. We also examined how tamoxifen influences the number of progenitor and mammary repopulating
units (MRUs).
Results: Our results indicate that ≥5 mg/25 g body weight of tamoxifen induces a transient increase in cell
proliferation and in the number of basal cells in the adult mammary epithelium up to 7 days after tamoxifen
administration. However, in the medium term (3 weeks), all doses of tamoxifen ≥1 mg/25 g body weight result in a
decrease in the number of basal and EpCAM+CD49b− luminal cells and a decrease in progenitor cell function.
Tamoxifen at doses ≥5 mg/25 g body weight induced a transient increase in caspase-3-mediated apoptotic cell
death within the mammary epithelium. However, mammary epithelial cell numbers in all subpopulations were
restored to their original levels by 8 weeks. No long-lasting effects of tamoxifen on MRU numbers or on pubertal
ductal development were observed.
Conclusion: Tamoxifen can skew the distribution of mammary cell types in a dose-dependent manner, and thus
caution must be taken when interpreting lineage-tracing studies using high doses of tamoxifen, particularly when
short-duration analyses of a quantitative nature are being performed.Introduction
Lineage tracing has emerged to become a powerful
method for establishing hierarchical relations between
stem and progenitor cells within epithelial tissues [1].
The main advantage of lineage-tracing strategies is that
they permit the interrogation of the growth and diffe-
rentiation potentials of distinct subsets of cells in a
homeostatic-tissue context, thus bypassing the artefacts
associated with tissue dissociation and transplantation
assays [2–4].
One common lineage-tracing approach involves the
use of a specific promoter to direct expression of Cre re-
combinase to defined subsets of cells, such that these* Correspondence: mona.shehata@cruk.cam.ac.uk; john.stingl@cruk.cam.ac.uk
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porter gene. By using an inducible system, the timing and
the proportion of cells that undergo genetic recombin-
ation can be refined, such that the contribution of specific
cells to tissues at defined developmental time points can
be interrogated at clonal densities. One common mecha-
nism includes the tamoxifen-inducible Cre recombinase
CreER, and the more refined CreERT2 [5–7].
One assumption of lineage tracing is that the inducing
agent itself (that is, tamoxifen) does not affect homeostasis
of the tissue under study. However, reports have demon-
strated that tamoxifen, at doses that are commonly used
to induce lineage tracing, can induce apoptosis within the
gastrointestinal tract and, and in some cases, can influence
the outcome of lineage-tracing experiments [8,9].
Considering that tamoxifen is an estrogen-receptor
(ER) antagonist and is a commonly used drug in thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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estrogen receptor+ (ER+) breast cancer cells [10], we
investigated the effects of a range of doses of tamoxifen
on the distribution and cell-division kinetics of the dif-
ferent mammary cell populations in the intact adult
mouse mammary gland. We also examined the influence
of tamoxifen on pubertal mammary gland development.
Our results indicate that tamoxifen, at relatively
high doses, induces a transient increase in cell pro-
liferation and basal cell numbers in the mammary
epithelium. In the longer term (3 weeks), all doses of
tamoxifen ≥1 mg/25 g mouse result in decreased numbers
of basal and EpCAM+CD49b− luminal cells and decreased
progenitor cell function, although these populations re-
cover by 8 weeks.
Methods
Mice and tamoxifen treatment
To determine the effects of tamoxifen on outgrowth of
the mammary epithelium during puberty, 23-day-old
C57BL/6 J mice received a single intraperitoneal (IP) in-
jection of sunflower oil, 1 mg of tamoxifen in oil/25 g
body weight, or 4 mg of tamoxifen in oil per 25 g body
weight. Mammary glands were harvested on postnatal
day 43 and stained with carmine alum for whole-mount
analysis.
To determine the effects of tamoxifen on the mammary
glands of adult mice, 10– to 14-week-old C57BL/6 J mice
were given a single IP injection of 0.2 mg, 1 mg, or 5 mg
tamoxifen (dissolved in 100% corn oil), or three IP injec-
tions of 5 mg every other day. Inguinal mammary glands
were then resected from the mice 1 to 56 days after the
last tamoxifen injection. The resected glands were then
dissociated and processed to a single-cell suspension, as
previously described [11]. Mice used for phenotypic ana-
lysis and colony-forming cell (CFC) assays were estrus
staged [12,13] immediately before culling and tissue
harvest. All mice were obtained from Charles River
(Hertfordshire, UK) and housed in open cages and pro-
vided with food and water ad libitum at the laboratory
animal facility at the Netherlands Cancer Institute and at
the Cambridge Institute. All experiments were conducted
in accordance with institutional guidelines and national
regulations, and all experimental procedures were ap-
proved by the Institutional Animal Care and Use Commit-
tee (DEC) of the Netherlands Cancer Institute and by the
Cambridge Institute Animal Ethics Committee.
Whole-mount carmine staining
The thoracic and inguinal mammary glands were flat
fixed for 4 hours in a 1:1 mixture of ethanol and acetic
acid. After fixation, the glands were washed with 70%
ethanol for 1 hour, rinsed in water, and stained overnight
in carmine alum staining solution. Stained glands werewashed in 100% ethanol and cleared in orange terpene
(Histoclear, National Diagnostics). All steps were carried
out at room temperature.
Measuring epithelial outgrowth
Carmine-stained mammary glands were photographed by
using a Leica MZFLIII stereomicroscope equipped with a
Nikon DXM1200 digital camera. Relative growth of the
mammary epithelium was scored in the inguinal glands by
drawing a tangent line, perpendicular to the distal edge of
the lymph node. A second line was drawn parallel to the
tangent at the most distal tip of the epithelium. The dis-
tance between these parallel lines was scored as “distance
from the lymph node”.
Flow cytometry
Mouse mammary cells were preblocked with 10% normal
rat serum and then incubated with the following primary
antibodies: CD31-biotin (clone 390, eBioscience), CD45-
biotin (clone 30-F11, eBioscience), Ter119-biotin (clone
Ter119, eBioscience), BP-1-biotin (clone 6C3, eBioscience),
EpCAM-APC (clone G8.8, BioLegend), CD49f-AF488
(clone GoH3, BioLegend), CD49b-PE (HMα2, BioLegend),
and Sca1-PE/Cy7 (clone D7, BioLegend). In some experi-
ments, cells were stained with CD24-PE (clone M1/69,
BioLegend) and CD29 (clone HMβ1-1, BioLegend). CD45,
Ter119, CD31, and BP-1 were used to deplete contaminat-
ing hematopoietic, endothelial, and a proportion of stromal
cells, respectively (collectively termed Lin + cells). Biotin-
conjugated antibodies were detected with Streptavidin-
APC-Cy7 (BioLegend). Cells were then filtered through a
30-μm cell strainer and incubated with 4′,6-diamidino-
2-phenylindole (DAPI; Invitrogen) and were analyzed by
using an LSRII (Becton Dickinson) and were sorted on a
FACSAria I (Becton Dickinson). The flow-cytometry gating
strategy was as previously described [11].
Mammary repopulating unit assay and in vitro CFC assays
For the MRU assays, donor cells were suspended in 65%
Hanks Balanced Salt Solution supplemented with 2%
fetal bovine serum (FBS), 25% Growth Factor Reduced
Matrigel (Becton Dickinson), and 10% Trypan Blue solu-
tion (0.4%, Sigma) at a concentration such that a 10-μl
injection volume contained the desired cell dose. The
endogenous mammary epithelium in the inguinal glands
of 3-week-old female C57BL/6 J mice was cleared, and
cells were injected into cleared fat pads, as previously
described [14]. The mice were mated 3 weeks after sur-
gery, and the inguinal glands were removed during preg-
nancy and glands fixed in Carnoy fixative and stained
with carmine alum. An outgrowth was scored positive if
it contained both lobular and ductal elements. MRU fre-
quencies were calculated by using the Extreme Limiting
Dilution Analysis (ELDA; [15]) tool.
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[11,16]. In brief, cell suspensions of 1,000 sorted mouse
luminal mammary cells were seeded in Mouse EpiCult-B
(StemCell Technologies) and 50 μg/ml gentamicin in the
presence of irradiated feeders for 6 to 7 days. In some
experiments in which 1,000 basal cells were seeded, FAD
media (3:1 DMEM/F12 (+1.8 × 10-4M adenine + 1.8 ×
10-3M calcium) + 10% FBS (PAA) + 0.5 μg/ml hy-
drocortisone (Sigma) + 10-10M cholera toxin (Enzo
Life Sciences) + 10 ng/ml epidermal growth factor
(EGF, Peprotech) + 5 μg/ml insulin + 10 μM Y-27632
(Sigma) + 50 μg/ml gentamicin) was used instead of
Mouse EpiCult-B.
At the end of the assays, the colonies were fixed with
acetone/methanol (1:1), stained with Giemsa (Fisher
Scientific), and enumerated under a microscope. CFCs
per pair of inguinal glands was calculated by multiplying
the cloning efficiency by the subpopulation cell number.
Immunofluorescence and immunohistochemistry
Paraffin-embedded mammary tissues were sectioned at
4 μm, deparaffinized, and boiled in pH 6.0 citrate buffer.
For immunofluorescence, sections were blocked in 1%
BSA/0.1% Tween-20/PBS for 1 hour and incubated with
primary antibodies specific for keratin 5 (Abcam), ER
(Novocastra), and Ki-67 (Dako) overnight at 4°C. Goat
anti-mouse, anti-rabbit, and anti-rat antibody conjugated
to Alexa Fluor (AF)555, AF647, and AF488, respectively,
were used to detect primary antibodies. No primary anti-
body was used as a control. Nuclei were visualized with
DAPI, and sections were mounted with ProLong Gold
Antifade (Invitrogen). Slides were scanned on the Leica
Ariol imaging system by using an Olympus BX61 micro-
scope (Leica).
Immunohistochemistry staining for Ki-67 (Dako) and
CC3 (Vector Labs) was performed on an automated
BondMax (Leica). Slides were scanned by using the Scan
ScopeXT Imaging System (Aperio).
Statistical analysis
Data presented are the means of multiple independent
mice (n = 4 to11 for all experiments except for the 0.2-mg
dose, for which n = 3–4) and the standard error of the
mean, except in Figure 1, where the standard deviation of
the mean is shown. Two-way analysis of variance was used
to test multiple groups followed by Dunnett multiple
comparisons test to test significant differences bet-
ween results. Significance was set at *P < 0.05, **P < 0.01,
or ***P < 0.0001.
A Fisher Exact test was performed on 10 contingency
tables measuring tamoxifen dosage against estrus stage
in mice over a series of days. The results were corrected
for multiple testing by using a Bonferroni correction.
Significance was set at P < 0.05.A Student t test was performed on the data depicted in
Figure 1. Significance was set at * P < 0.05 and **P < 0. 01.
Results
Tamoxifen inhibits outgrowth of the mammary
epithelium during puberty
Tamoxifen-mediated Cre recombination has been used
successfully to label cells in the mammary gland at
different developmental time points, but the dose of
tamoxifen used to achieve sufficient labeling varies bet-
ween studies (Additional file 1: Table S1).
To determine the effects of tamoxifen on ductal devel-
opment, we injected wild-type C57BL/6 J mice with either
a low (1 mg/25 g) or a high (4 mg/25 g) dose of tamoxifen
at the onset of puberty. Next, we measured outgrowth of
the mammary epithelium approximately 3 weeks later and
compared the extent of growth from tamoxifen-treated
mice with that of mice that had received an injection only
with sunflower oil. Our measurements show that even a
low dose of tamoxifen (1 mg/25 g), administered during
puberty, significantly delays mammary gland development
(Figure 1A). A similar reduction in pubertal ductal deve-
lopment has been reported when tamoxifen is admi-
nistered to neonatal mice [17]. In addition, high doses of
tamoxifen result in an apparent collapse of terminal-end
bud structures in both the inguinal and the thoracic gland
(Figure 1B-E). Despite this inhibition, ductal development
ultimately catches up, and complete ductal outgrowth was
eventually obtained in adult mice [4], which is consistent
with a previous report [18].
We next set out to test the immediate and long-term
effects of different doses of tamoxifen on the different
mammary cell types in adult mice.
Tamoxifen skews the distribution of epithelial cells in the
mammary gland
Mouse mammary epithelial cell populations can be re-
solved by flow cytometry on the basis of differential expres-
sion of EpCAM, CD49f, Sca1, and CD49b (Figure 2C, top
panels). Basal cells have an EpCAMlowCD49fhigh pheno-
type, whereas undifferentiated and differentiated luminal
progenitors have an Sca1−CD49b+ and an Sca1+CD49b+
phenotype, respectively. The most-differentiated cell popu-
lation, the non-clonogenic luminal (NCL) cells, have an
Sca1+CD49b− phenotype [11].
To investigate the influence of tamoxifen on these dif-
ferent cell populations, adult female mice were injected
with either corn oil or with 1 mg or 5 mg of tamoxifen.
Mice were culled 1 and 2 days later, and the absolute
number of cells of different phenotypes per pair of
inguinal glands was enumerated by cell counting and
flow-cytometry analysis. We observed that by day 2, the
5-mg dose of tamoxifen caused a slight decrease in the
number of luminal cells present in the mammary gland
Figure 1 Tamoxifen temporarily retards ductal elongation during pubertal mammary gland development. (A) Bar graph depicting the
quantification of mammary gland outgrowth, showing relative elongation of the inguinal mammary gland between P23 and P43 in mice treated
with sunflower oil (n = 4), 1 mg/25 g of tamoxifen (n = 4), or 4 mg/25 g of tamoxifen (n = 4). The position of the most distal tip of the lymph
node is set at zero. (*P < 0.05, **P < 0.01). (B) Whole-mount preparations of carmine alum-stained mammary epithelium, showing representative
images of the inguinal glands quantified in panel (A). Arrows indicate the relative outgrowth of the epithelium. Scale bar = 500 μm. (C) Close-up of the
glands depicted in (B), showing loss of terminal-end bud structures in mice treated with 4 mg/25 g tamoxifen. Scale bar = 20 μm. (D) Whole-mount
carmine alum staining of thoracic glands. Scale bar = 500 μm. (E) Close-up of thoracic glands depicted in (D). Scale bar = 20 μm.
Shehata et al. Breast Cancer Research 2014, 16:411 Page 4 of 11
http://breast-cancer-research.com/content/16/1/411(Figure 2A). Unexpectedly, we also observed a 56% in-
crease in the number of basal cells within the mammary
epithelium compared with oil control.
We then repeated these experiments by using a broader
range of tamoxifen doses (0.2 mg, 1 mg, 5 mg, or
3 × 5 mg) and analyzed the mice at 3, 7, 21, and 56 days
after the last injection. We observed that the previously
observed increase in basal cell number was only transient,
because it was no longer detected after 3 or more days. In
mice injected with ≥1 mg of tamoxifen and analyzed
21 days later, the absolute number of both basal and NCL
cells had decreased by 61%, 40%, and 44% and 32%, 51%,
and 64%, in 1 mg, 5 mg, and 3 × 5 mg, respectively, al-
though the two luminal progenitor populations remained
unchanged (Figure 2B). We also observed a slight decrease
in the stromal population at the highest tamoxifen dose,and this may be because the stromal compartment, like
many of the luminal epithelial cells, also expresses ER
[19]. When the experiment was extended to 56 days, the
number of basal and NCL cells recovered to that of the oil
control for all doses (Figure 2B). The proportions of these
subpopulations relative to each other in control and
tamoxifen-treated mice is shown in Additional file 2:
Figure S1.
We observed that the phenotypes of these cells changed
after administrating the higher doses (5 and 3 × 5 mg) of
tamoxifen. The luminal and basal cell populations, which
are normally resolved as two distinct subpopulations on a
dot plot, began to merge with one another in tamoxifen-
treated mice (Figure 2C, lower panels, and see Additional
file 3: Figure S2). When the luminal subpopulations were
back-gated, we observe that this gain in CD49f expression
Figure 2 High doses of tamoxifen can skew the relative distribution of mammary cell populations over time. Absolute number of
different types of mammary cells per pair of inguinal glands treated with varying doses of tamoxifen and analyzed at (A) 1 and 2 or (B) 3, 7, 21,
and 56 days after tamoxifen injection (*P < 0.05; **P < 0.01; ***P < 0.0001). (C) Representative flow-cytometry dot plots show the expression of EpCAM,
CD49f, Sca1, and CD49b among mammary cells from control mice and mice treated with 3 × 5 mg tamoxifen and analyzed 21 (left panels) or 56 days
(right panels) later.
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NCL cells (Additional file 4: Figure S3A). Examination of
the effects of tamoxifen on the expression of the mam-
mary epithelial markers CD24 and CD29 revealed thatthese markers are not influenced by tamoxifen, as no dis-
cernable differences in the dot plots were observed bet-
ween control mice and mice receiving high doses of
tamoxifen (Additional file 4: Figure S3B).
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CFCs but not MRUs in mammary glands
When we examined the influence of tamoxifen on the
cloning efficiency of purified subpopulations of epithelial
cells, we observed that, in general, only the higher doses
(5 mg and 3 × 5 mg) influenced the cloning efficiencies
(Figures 3A and Additional file 5: Figure S4). This effect
was seen for the basal cells, Sca1− luminal progenitors,Figure 3 Tamoxifen can decrease the number of CFCs in the mamma
per pair of inguinal mammary glands in mice treated with varying doses of ta
**P < 0.01; ***P < 0.0001); n = 5 to 11 for all experiments, except for 0.2-mg doand the Sca1+ luminal progenitors, but only at 7 and
21 days after tamoxifen administration. We also ob-
served that a 1-mg dose of tamoxifen did result in a
slight decrease in the cloning efficiency of Sca1− luminal
progenitors per 1,000 cells plated and detected 21 days
later (Figure 3A). However, when we corrected this
for total population size by multiplying the cloning
efficiency with cell number, we observed that the totalry epithelium. (A) Cloning efficiency and (B) total number of CFCs
moxifen and analyzed at 3, 7, and 21 days after treatment. (*P < 0.05;
se, where n = 3 to 4.
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not discernibly change with tamoxifen treatment. How-
ever, tamoxifen did have a profound effect on the basal
compartment, where even doses of 1 mg tamoxifen sig-
nificantly decreased the absolute number of basal pro-
genitors present in the glands at 21 days after treatment
(Figure 3B).
We interrogated the effects of tamoxifen on the num-
ber of MRUs present in the mammary gland. We ob-
served that mammary glands of mice treated with 1 mg
and 5 mg of tamoxifen had no statistical differences in
the frequency of MRUs when compared with oil-treated
controls when examined 3 days (1 mg = 1 MRU in 1,850
cells; 5 mg = 1 MRU in 361 cells) and 21 days (1 mg = 1
MRU in 326 cells; 5 mg = 1 MRU in 467 cells) after
tamoxifen injection (Additional file 6: Table S2).
One unusual observation that we noted during the
course of these experiments is that mice treated with
higher doses of tamoxifen tended to have an increased
probability of being in metestrus than in other stages of
the estrus cycle (Additional file 7: Table S3). Although
statistical significance was not obtained for this obser-
vation, two different time points (Day 3 and Day 7) de-
monstrate a trend for this phenomenon (P = 0.06 and
0.07, respectively). This effect is transient, and mice
examined at the Day 21 time point did not exhibit this
behavior.
Tamoxifen induces short-term cell proliferation and cell
death in the mammary epithelium
Given the change in basal and luminal cell numbers after
tamoxifen application, we next examined the effect on
proliferation of mammary epithelial cells. We observed an
increase of Ki-67+ cells and the luminal cells forming
a thick pluristratified epithelium in mammary glands
of mice that received the highest doses of tamoxifen
(Figure 4A). To ensure that this observation of increased
Ki-67+ in mammary epithelial cells is due to tamoxifen ad-
ministration and not a delay in puberty, we repeated this
experiment by using 14-week-old mice and observed the
same phenomenon (Figure 4A). This increase in prolifera-
tion is evident at the Day 3 time point for the 3 × 5-mg
tamoxifen dose and at the Day 7 time point for the 5-mg
dose (Figure 4B). Because the highest dose (3 × 5 mg) is
administrated over several days, this results in a total of
7 days after the first 5-mg injection, and thus the effect is
similar to the result observed with the 5-mg dose. At high
tamoxifen doses (5 mg or 3 × 5 mg), tamoxifen increases
the proportion of proliferating ER+ cells and decreases the
proportion of proliferating basal cells compared with oil
controls (Figure 4C, D).
To assess whether this transient increase in cell prolife-
ration is accompanied by increased apoptosis, we also im-
munostained mammary tissue sections to detect cleavedcaspase-3 (CC3), one of the key executioners of apoptosis.
We observed a biphasic increase in the number of CC3+
cells in mammary glands of mice that received a 5-mg
tamoxifen dose, with peaks on Day 1 and Day 7. A peak in
apoptotic cells on 3 days after the last injection was
observed when mice were administered three successive
5-mg doses spread over 5 days, which correlates to 7 days
after the first dose. Although tamoxifen could increase the
frequency of CC3+ within the mammary glands, the over-
all frequency of apoptotic cells in both oil- and all
tamoxifen-treated mice is exceedingly low (Figure 5A, B).
The frequency of this tamoxifen-induced apoptosis is likely
an underestimate of the true frequency, because it would
be expected that resident macrophages would quickly clear
the dying cells. As well, the presence of CC3+ cells at any
one point of time would likely not be representative of the
total amount of apoptosis if cell death were nonsynchro-
nous within the epithelial cell population.
Similar patterns exist between increased proliferation
and cell death, whereby increased numbers of CC3 cells
can be detected up to 7 days after initial 5-mg or 3 × 5-mg
tamoxifen injections (Figure 5B). By 21 days after tamo-
xifen administration, a trend in the number of both pro-
liferating and dying cells in the higher doses, although this
is not significant (Figures 4B and 5B). Taken together, this
indicates that tamoxifen is stimulating proliferation as well
as a low degree of apoptosis within a short period after
tamoxifen administration.
Discussion
Inducible lineage tracing has rapidly become the new gold
standard in assessing cell fate and identifying stem cells in
intact tissues [1,2,4,20,21]. Most lineage-tracing models
described to date rely on the tamoxifen-induced CreERT2-
mediated recombination. The doses commonly used by
researchers to obtain recombination in the mammary
epithelium tend to be higher than those used for other or-
gans, and the concern arises that these high doses of
tamoxifen may have unrecognized off-target effects that
may influence the fate of the cells under study. The results
presented here show that tamoxifen, at least during the
first 3 weeks after administration, decreases overall mam-
mary epithelial cellularity in a dose-dependent manner,
with NCL and basal cells being particularly affected,
although this cellularity is restored by 8 weeks after injec-
tion. Surprisingly, we observed that higher doses (for
example, 5 mg) of tamoxifen caused a transient short-
term increase in the number of basal and proliferating
cells in the epithelium. The mechanism behind this is not
clear, but we hypothesize that this is mediated by in-
creased levels of circulating female sex steroid hormones,
because previous studies in humans demonstrated that
tamoxifen can transiently increase estrogen produc-
tion from the ovaries [22–24], and a study in mice
Figure 4 Tamoxifen can induce short-term proliferation of mammary epithelial cells. (A) Ki-67-immunostained sections of mammary glands
from oil- and tamoxifen-treated mice at selected time points for 10–week- and 14-week-old treated mice. Scale bars = 50 μm. (B) Frequency of
Ki-67+ cells in mammary glands of mice treated with oil or varying doses of tamoxifen, and analyzed at multiple time points. (C) Representative
immunofluorescent sections of mammary glands from oil- and tamoxifen-treated glands at time points Days 3 and 7. Shown is the expression of
keratin 5 (yellow), ER (red), and Ki-67 (green). Nuclei were visualized with DAPI. Scale bar = 25 μm. (D) Proportion of proliferating ER− luminal cells,
ER+ luminal cells, and basal cells in tamoxifen-treated glands. (*P < 0.05; **P < 0.01; ***P < 0.0001).
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crease circulating progesterone levels [17].
Related to this, we also observed that tamoxifen can
induce transient skewing of the estrus cycle, because
mice treated with high doses of tamoxifen tend to have
an increased probability of being staged in metestrus.
The mechanism responsible for this phenomenon is not
known.
We observed that tamoxifen induces a transient delay
in pubertal ductal development. A similar observation
was recently reported by the Visvader laboratory [25].
This is not surprising, considering that tamoxifen is a
cytostatic compound that causes cells to remain in early
G1 phase of the cell cycle [26,27]. We hypothesize that
this delay in development is the result of the time ittakes for tamoxifen to be cleared from the mammary
tissue, because it was previously reported that tamoxifen
and its metabolites are detectable in mice 7 days after
administration of doses (for example, 5 mg/25 g) com-
parable to those described here [28].
We report that high doses of tamoxifen (for example,
3 × 5 mg) cause the NCL cells to increase their ex-
pression of CD49f. A similar dose-dependent effect of
tamoxifen on Itga6 transcription was previously reported
for uterine cells [29]. ITGA6, the gene that encodes
CD49f, has been previously reported to be regulated by
ERα [30], and the data presented here suggest that tamo-
xifen has similar agonist activities on Itga6 transcription.
We did not observe a dose-dependent effect of tamoxifen
on CD29, and we would suggest that this marker would
Figure 5 Tamoxifen can induce slight short-term apoptotic activity in mammary epithelial cells. (A) CC3 immunostained sections of
mammary glands from oil- and tamoxifen-treated mice at selected time points. Arrows indicate CC3-positive cells. (B) Bar charts depicting the number
of CC3+ cells per pair of oil- and tamoxifen-treated glands analyzed at 1, 2, 3, 7, and 21 days after treatment. (*P < 0.05; **P < 0.01; ***P < 0.0001).
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cell populations from tamoxifen-treated mice with flow
cytometry.
It is not known whether these off-target effects of
tamoxifen influence the fate of the cells in lineage-
tracing experiments in the mammary gland. However,
lineage-tracing experiments using doxycycline-inducible
K14-rtTA/TetO-Cre mice have yielded results similar to
those in tamoxifen-inducible K5-CreER mice [2]. Be-
cause K14 and K5 have similar, if not identical distribu-
tions in the mouse mammary epithelium, this suggests
that tamoxifen does not adversely affect the fate of the
cells in these experiments.
It was demonstrated that in the intestine, tamoxifen
reduces the efficiency of lineage tracing from Lgr5+ cells.
Moreover, it induces apoptosis of the Bmi-1+ cells in theintestinal crypt, and the stem cell properties of these
cells are greatly reduced unless apoptosis is suppressed
[9]. Tamoxifen is known to induce apoptosis by multiple
mechanisms in mammary tumor cells [31], including
caspase-3-mediated apoptosis [32]. We observed an induc-
tion of caspase-3-mediated apoptosis in the mammary epi-
thelium on administration of doses of tamoxifen >5 mg.
This response appears to be biphasic, with a peak in
apoptosis 1 day and 7 days after tamoxifen administration.
It previously was reported that progesterone can induce a
biphasic proliferation response in the mouse mammary
epithelium, with an early immediate direct response and a
delayed second wave via paracrine factors [33]. We hypo-
thesize that an opposite, but analogous biphasic response
is occurring with tamoxifen treatment; that is, tamoxifen
induces immediate apoptosis in some cell types (the first
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actions, a second wave several days later. However, it is
important to note that the overall levels of CC3-mediated
apoptotic cell death were still very low when compared
with the total epithelial cell population at all tamoxifen
doses tested. Whether the off-target effects of tamoxifen
can influence the results of a lineage-tracing experiment
will ultimately depend on the gene promoter being used to
direct the trace, the dose of tamoxifen used, and the du-
ration of the experiment. However, our results demon-
strate that caution and, where possible, controls must be
taken when interpreting short-duration lineage-tracing
studies that are of a quantitative nature, especially when
using high doses of tamoxifen.Conclusion
The advantage of inducible lineage tracing is that it per-
mits the interrogation of the fate of cells at a clonal level
in intact tissues, with the assumption that the lineage trace
itself does not influence the homeostatic state of the tis-
sue. Data presented here demonstrate that a single short-
term exposure of tamoxifen at doses that are commonly
used in mammary lineage-tracing studies can transiently
increase basal cell numbers and cell proliferation with-
in the mammary epithelium, although in the midterm
(~3 weeks), a general decrease is found in the cellularity
of the epithelium. However, by 8 weeks, all epithelial cell
populations are restored to their original levels.
Higher doses of tamoxifen can also induce a transient
increase in caspase-3-mediated apoptosis and transient
disruptions in normal estrus cycling. No long-lasting
effects of tamoxifen on MRU numbers are observed.
Although these results do not diminish the power and
utility of inducible lineage-tracing studies, they do indi-
cate that potential off-target effects should be considered
during the design and analysis of these experiments.Additional files
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